Recent Federal Developments Targeting China-Linked Companies and Overseas Biotechnology Investments and Collaboration

In recent weeks, Congress and the Administration have escalated scrutiny of China-linked biotechnology, pharmaceutical development, and related intellectual property. The developments below signal that the landscape for companies with China-linked operations, partnerships, or investments is shifting rapidly and warrants close monitoring and active planning….
By: Foley Hoag LLP